EUVIMEDEUVIMED entdecken
Open Access

Cost Sharing for Preferred Branded Drugs in Medicare Part D

Erin Trish, Barbara Blaylock, Karen Van Nuys

JAMA · 01.04.2025 · 333 (13) · 1170

DOI: 10.1001/jama.2024.28092 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 01.04.2025. Verfasst von Erin Trish und 2 weiteren Autor:innen. Beteiligte Einrichtung: Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study uses data from the Centers for Medicare & Medicaid Services Public Use Files to examine the use of co-payments and co-insurance for preferred brand-name drugs among Medicare Part D plans from 2020 to 2024 and characterize beneficiary exposure to these trends.

Autor:innen und Institutionen

  • Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles.
  • Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles.
  • Blaylock Health Economics LLC, Reno, Nevada.

Zitieren

APA

Trish, E., Blaylock, B., & Van Nuys, K. (2025). Cost Sharing for Preferred Branded Drugs in Medicare Part D. JAMA, 333(13), 1170. https://doi.org/10.1001/jama.2024.28092

Vancouver

Trish E, Blaylock B, Van Nuys K. Cost Sharing for Preferred Branded Drugs in Medicare Part D. JAMA. 2025;333(13):1170. doi:10.1001/jama.2024.28092

BibTeX
@article{Trish2025,
  author = {Trish, Erin and Blaylock, Barbara and Van Nuys, Karen},
  title = {Cost Sharing for Preferred Branded Drugs in Medicare Part D},
  journal = {JAMA},
  year = {2025},
  volume = {333},
  number = {13},
  pages = {1170},
  doi = {10.1001/jama.2024.28092}
}
Kostenlos starten →